Home Cart Sign in  
Chemical Structure| 1610759-22-2 Chemical Structure| 1610759-22-2

Structure of CFI-402257
CAS No.: 1610759-22-2

Chemical Structure| 1610759-22-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CFI-402257 is a novel and selective Mps1 inhibitor with Ki value of 0.1 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CFI-402257

CAS No. :1610759-22-2
Formula : C28H30N6O3
M.W : 498.58
SMILES Code : O=C(NC1CC1)C2=CC=C(C3=C4N=C(OC5=CC=CN=C5)C=C(NC[C@H]6C[C@](C)(O)C6)N4N=C3)C=C2C
MDL No. :MFCD31382135
InChI Key :PMQUGSPFUBGJCZ-UHFFFAOYSA-N
Pubchem ID :118086034

Safety of CFI-402257

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of CFI-402257

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Normal mesothelial cells 20-40 nM 5 days CFI-402257 had no significant effect on normal mesothelial cells at the same concentrations. Oncogene. 2017 Nov 16;36(46):6501-6507.
U87 cells 1 μM 48 hours To evaluate the effect of CFI-402257 on the proliferation of U87 cells, results showed that CFI-402257 significantly inhibited the proliferation of U87 cells. BMC Cancer. 2022 Jul 18;22(1):786.
U251 cells 0.5 μM 48 hours To evaluate the effect of CFI-402257 on the proliferation of U251 cells, results showed that CFI-402257 significantly inhibited the proliferation of U251 cells. BMC Cancer. 2022 Jul 18;22(1):786.
RB1-deficient ER+ breast cancer cell lines 150 nM 72 hours To assess the impact of RB1 loss on sensitivity to CFI-402257, results showed that RB1-deficient cells were more sensitive to CFI-402257, inducing higher levels of apoptosis Sci Adv. 2022 Sep 9;8(36):eabq4293.
ER+ breast cancer cell lines 150 nM 48 hours To evaluate the sensitivity of CDK4/6i-resistant cells to CFI-402257, results showed that CFI-402257 induced premature chromosome segregation, increased DNA damage, and cell death Sci Adv. 2022 Sep 9;8(36):eabq4293.
Myla3676 cells 10 μM or 20 μM 48 hours Inhibited cell proliferation, induced G2/M phase arrest, promoted apoptosis Adv Sci (Weinh). 2025 Mar;12(10):e2413990.
Jurkat cells 10 μM or 20 μM 48 hours Inhibited cell proliferation, induced G2/M phase arrest, promoted apoptosis Adv Sci (Weinh). 2025 Mar;12(10):e2413990.
MHCC97L 500 nM 48 hours Induced micronuclei formation and DNA damage Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2119514119.
HCT116 cells 100 nM 2 days CFI-402257 induced aneuploidy, accompanied by accumulation of apoptotic cells Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
HCT116 cells 200 nM 2 hours CFI-402257 caused chromosome missegregation, increasing the percentage of lagging chromosomes Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
MDA-MB-436 150 nM 72 hours induced apoptosis and potentiated aneuploidy Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577.
MDA-MB-468 150 nM 72 hours induced apoptosis and potentiated aneuploidy Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577.
MDA-MB-231 150 nM 72 hours induced apoptosis and potentiated aneuploidy Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577.
MCF-7 cells 0-1000 nM 72 hours Evaluate the cytotoxicity of CFI-402257, results showed lower toxicity in MCF-7 cells Oncol Rep. 2024 Aug;52(2):101.
HMEC cells 0-1000 nM 72 hours Evaluate the cytotoxicity of CFI-402257, results showed lower toxicity in HMEC cells Oncol Rep. 2024 Aug;52(2):101.
MDA-MB-231 cells 0-1000 nM 72 hours Evaluate the cytotoxicity of CFI-402257, results showed CFI-402257 selectively induced cytotoxicity in MDA-MB-231 TNBC cells Oncol Rep. 2024 Aug;52(2):101.
Malignant mesothelioma cell lines 100 nM 30 minutes to 72 hours CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe. Oncogene. 2017 Nov 16;36(46):6501-6507.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Orthotopic, syngeneic model of malignant mesothelioma Oral gavage 7 mg/kg Daily, till study end-point CFI-402257 significantly reduced tumor growth as a single agent and showed enhanced effect when combined with cisplatin+pemetrexed. Oncogene. 2017 Nov 16;36(46):6501-6507.
Mice Carotid artery wire injury model and HFD-fed ApoE−/− mice Oral 1, 2, or 4 mg/kg body weight Once daily for 28 days (wire injury model) or 12 weeks (atherosclerosis model) To evaluate the effect of CFI-402257 on postinjury neointimal formation and atherosclerosis, results showed it significantly inhibited neointimal formation and atherosclerotic plaque area without impairing reendothelialization Adv Sci (Weinh). 2025 Feb;12(6):e2409250.
SCID mice MCF7 RB1-deficient xenograft model Oral administration 6 mg/kg (daily) and 25 mg/kg (2 days on/5 days off) Daily or 2 days on/5 days off, for up to 38 days To evaluate the antitumor activity of CFI-402257 in RB1-deficient tumors, results showed that CFI-402257 significantly inhibited tumor growth Sci Adv. 2022 Sep 9;8(36):eabq4293.
SCID beige mice TCL xenograft model Oral 6 mg/kg/day Once daily for one week Inhibited tumor growth, reduced tumor volume and weight Adv Sci (Weinh). 2025 Mar;12(10):e2413990.
BALB/cAnN-nu mice HCC model Oral 6 mg/kg/day Once daily for 19 days Assessed the inhibitory effect of CFI-402257 on HCC growth Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2119514119.
Mice MDA-MB-231 human TNBC xenograft model Oral 6 mg/kg Once daily for 22 days CFI-402257 significantly inhibited tumor growth with a TGI of 89% Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
BALB/c nude mice MDA-MB-231 xenograft model Oral and intraperitoneal injection 1 mg/kg Once daily for 28 days Evaluate the antitumor effect of CFI-402257 and AICAR combination therapy, results showed significant tumor growth inhibition Oncol Rep. 2024 Aug;52(2):101.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.01mL

0.40mL

0.20mL

10.03mL

2.01mL

1.00mL

20.06mL

4.01mL

2.01mL

References

 

Historical Records

Categories